PAK4 and neoplasm: Additionally, targeted knockout of p21-activated kinase 4 (PAK4) reprograms the transcriptome of tumor ECs through specific mechanisms, reduces vascular permeability, and reduces T cell adhesion to ECs, thus providing a novel therapeutic strategy to improve tumor vascular microenvironment and enhance immunotherapy efficacy (Ma et al., 2021).